- Home
- DOUG vs MSLE Comparison
DOUG vs MSLE Comparison
Compare DOUG & MSLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DOUG | MSLE |
|---|---|---|
| Founded | 1911 | N/A |
| Country | United States | Canada |
| Employees | N/A | 17 |
| Industry | Building operators | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 162.3M | 146.9M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | DOUG | MSLE |
|---|---|---|
| Price | $2.10 | $7.50 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 436.6K | 41.4K |
| Earning Date | 05-05-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 118.68 | N/A |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $955,578,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.15 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.53 | $5.50 |
| 52 Week High | $3.20 | $13.39 |
Technical Indicators
Market Signals| Indicator | DOUG | MSLE |
|---|---|---|
| Relative Strength Index (RSI) | 59.68 | 49.16 |
| Support Level | $2.00 | $6.73 |
| Resistance Level | $2.87 | $9.50 |
| Average True Range (ATR) | 0.11 | 0.64 |
| MACD | 0.03 | 0.05 |
| Stochastic Oscillator | 78.69 | 39.28 |
Price Performance
Historical ComparisonAbout DOUG Douglas Elliman Inc.
Douglas Elliman Inc is engaged in the real estate services business and seeks to acquire or invest in additional real estate services businesses. The Company also offers, through its subsidiaries and ventures, development marketing services and ancillary services, including mortgage, title, and escrow services. It generates revenue from commissions and other brokerage income, property management, and other ancillary services.
About MSLE Satellos Bioscience Inc. Common Stock
Satellos Bioscience Inc is a regenerative medicine company a biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease.